...
首页> 外文期刊>Techniques in coloproctology >Treatment of fistula-in-ano using a porcine small intestinal submucosa anal fistula plug.
【24h】

Treatment of fistula-in-ano using a porcine small intestinal submucosa anal fistula plug.

机译:使用猪小肠粘膜下层肛瘘塞治疗肛瘘。

获取原文
获取原文并翻译 | 示例
           

摘要

Porcine small intestinal submucosa (SIS) is a bioprosthetic collagen material used in the management of various surgical conditions, especially hernia repairs. We studied the effectiveness of porcine SIS Bioprosthetic plug (Surgisis AFP, Cook Biotech Inc., West Lafayette, IN, USA) in the treatment of fistula-in-ano.A prospective multi-institutional study was conducted on 73 patients with anorectal fistulas of differing etiologies. All plugs were inserted in the operating room under anesthesia in patients with preoperative bowel preparation. Regular follow-up was scheduled at 2 weeks, 3, 6, and 12 months. The primary end point was complete closure of the fistula and cessation of drainage over the follow-up period. Seventy-eight AFPs were inserted in 73 patients (28 women and 45 men). Rectovaginal fistulas were excluded. Crohn's disease accounted for 11% (8/73) of the patients. Seventy-three percent of patients (n = 53) had primary fistulas whereas 27% (N = 20) had recurrent fistulas.The plug extrusion (fallout) rate was 9% (7/78). There was no difference in closure rates between primary and recurrent fistulas (primary = 20/53 = 38% and recurrent 8/20 = 40%). The overall patient success rate was 38% (28/73) and the plug success rate was 39.5% when plug fallouts were eliminated. The fistulas in four out of eight patients with Crohn's disease closed (50%). There were no intraoperative complications. There were four postoperative abscesses (4/73; 5%).Use of AFP for treatment of fistula-in-ano is safe and modestly effective in reasonable long-term (15 months) follow-up. This sphincter conserving procedure should be included in the armamentarium of surgeons in the management of transsphincteric or suprasphincteric fistulas.
机译:猪小肠粘膜下层(SIS)是一种生物义肢胶原材料,可用于管理各种手术条件,尤其是疝气修复。我们研究了猪SIS生物假体塞(Surgisis AFP,Cook Biotech Inc.,West Lafayette,IN,USA)在治疗肛瘘中的有效性。一项针对73例肛肠瘘患者的前瞻性多机构研究不同的病因。术前准备肠道的患者在麻醉下将所有塞子插入手术室。定期随访计划在2周,3、6和12个月进行。主要终点是在随访期间完全关闭瘘管并停止引流。在73例患者(28名女性和45名男性)中插入了78个AFP。排除了直肠阴道瘘。克罗恩病占患者的11%(8/73)。 73%(n = 53)的患者患有原发性瘘管,而27%(N = 20)的患者有复发性瘘管。栓塞挤出(脱落)率为9%(7/78)。初发和复发性瘘管的闭合率没有差异(初发= 20/53 = 38%,复发性8/20 = 40%)。排除栓塞后,总的患者成功率为38%(28/73),栓塞成功率为39.5%。八分之一的克罗恩病患者中有四分之三的瘘管闭合(50%)。没有术中并发症。术后有4例脓肿(4/73; 5%)。在合理的长期(15个月)随访中,使用AFP治疗肛瘘是安全且适度的。保留括约肌的程序应包括在经括约肌或括约肌上瘘管治疗的外科医生武器库中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号